The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined to approve ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

Key Takeaways House Bill 3749, also known as Jenifer’s Law, goes into effect on September 1, 2025, and applies only to ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...